PMID- 35360511
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220402
IS  - 2213-0489 (Print)
IS  - 2213-0489 (Electronic)
IS  - 2213-0489 (Linking)
VI  - 17
DP  - 2022
TI  - Delayed kidney transplantation after HLA-haploidentical hematopoietic cell 
      transplantation in a young woman with myelodysplastic syndrome with renal 
      failure.
PG  - 100302
LID - 10.1016/j.lrr.2022.100302 [doi]
LID - 100302
AB  - Patients with end-stage renal disease (ESRD) are often excluded from potentially 
      curative allogeneic hematopoietic cell transplantation (alloHCT). Our institution 
      pioneered simultaneous living donor kidney transplantation in patients undergoing 
      alloHCT from the same donor for hematologic malignancies. Herein, we present the 
      case of a 31-year-old woman diagnosed with myelodysplastic syndrome who developed 
      ESRD during cytoreductive induction therapy. She achieved disease control, then 
      successfully underwent a human leukocyte antigen (HLA)-haploidentical alloHCT 
      while on hemodialysis. After rapidly tapering off graft-versus-host disease 
      prophylaxis, fourteen months from her alloHCT she received a kidney transplant 
      from her same haploidentical sibling donor, which obviated the need for further 
      systemic immunosuppression.
CI  - (c) 2022 The Authors. Published by Elsevier Ltd.
FAU - Miller, Kevin C
AU  - Miller KC
AD  - Department of Medicine, Massachusetts General Hospital, Boston, MA, United 
      States.
FAU - Hall, Aric C
AU  - Hall AC
AD  - Division of Hematology, Medical Oncology and Palliative Care, University of 
      Wisconsin School of Medicine and Public Health, Madison, WI, United States.
FAU - Cohen-Bucay, Abraham
AU  - Cohen-Bucay A
AD  - Renal Division and Transplant Center, Massachusetts General Hospital, Boston, MA, 
      United States.
FAU - Chen, Yi-Bin
AU  - Chen YB
AD  - Hematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General 
      Hospital, Boston, MA, United States.
LA  - eng
PT  - Case Reports
DEP - 20220317
PL  - England
TA  - Leuk Res Rep
JT  - Leukemia research reports
JID - 101608906
PMC - PMC8961207
OTO - NOTNLM
OT  - Haploidentical
OT  - Hematopoietic cell transplant
OT  - Kidney transplant
OT  - Stem cell transplant
COIS- K.C.M., A.C.H. and A.C.B. declare no competing financial interests. Y-B.C. has 
      performed consultancy for Daiichi, Equilium, Actinium, Celularity, and Incyte.
EDAT- 2022/04/02 06:00
MHDA- 2022/04/02 06:01
PMCR- 2022/03/17
CRDT- 2022/04/01 05:23
PHST- 2021/11/01 00:00 [received]
PHST- 2022/03/16 00:00 [accepted]
PHST- 2022/04/01 05:23 [entrez]
PHST- 2022/04/02 06:00 [pubmed]
PHST- 2022/04/02 06:01 [medline]
PHST- 2022/03/17 00:00 [pmc-release]
AID - S2213-0489(22)00014-0 [pii]
AID - 100302 [pii]
AID - 10.1016/j.lrr.2022.100302 [doi]
PST - epublish
SO  - Leuk Res Rep. 2022 Mar 17;17:100302. doi: 10.1016/j.lrr.2022.100302. eCollection 
      2022.